TY - JOUR
T1 - Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues
AU - Takeuchi, H.
AU - Baba, H.
AU - Inutsuka, S.
AU - Takahashi, I.
AU - Kusumoto, H.
AU - Maehara, Y.
AU - Sugimachi, K.
PY - 1994
Y1 - 1994
N2 - The chemosensitivity of 43 human sarcoma tissues, including 18 osteosarcomas, 16 leiomyosarcomas and 9 liposarcomas was compared with that of 28 adenocarcinomas of the stomach using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues were exposed for 3 days to each antitumor drug including adriamycin (ADM), 5-fluorouracil (5-FU), mitomycin C (MMC), cisplatin (CDDP), aclacinomycin A (ACR) and carboquone (CQ), then the cell viability was estimated based on the succinate dehydrogenase (SD) activity determined using [3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H tetrazolium bromide] (MTT). SD activity was significantly lower in the osteosarcoma as compared to that in the adenocarcinoma for ADM, MMC, CDDP, ACR and CQ (p < 0.01) and was higher for ADM (p < 0.05) in cases of leiomyosarcoma and for CDDP (p < 0.01) and ACR (p < 0.05) in cases of liposarcoma. The sensitivity rate was higher in osteosarcoma than in adenocarcinoma for ADM, MMC and CDDP. These findings suggest that patients with osteosarcoma will probably show a fairly good response to antitumor drugs and that when liposarcoma or leiomyosarcoma tumors show resistance to antitumor drugs then resection at the time of initial exploration and combined modalities, including radiation and hyperthemia should be considered.
AB - The chemosensitivity of 43 human sarcoma tissues, including 18 osteosarcomas, 16 leiomyosarcomas and 9 liposarcomas was compared with that of 28 adenocarcinomas of the stomach using the in vitro succinate dehydrogenase inhibition (SDI) test. These tissues were exposed for 3 days to each antitumor drug including adriamycin (ADM), 5-fluorouracil (5-FU), mitomycin C (MMC), cisplatin (CDDP), aclacinomycin A (ACR) and carboquone (CQ), then the cell viability was estimated based on the succinate dehydrogenase (SD) activity determined using [3-(4,5-dimethyl-2-thiazolyl) -2,5-diphenyl-2H tetrazolium bromide] (MTT). SD activity was significantly lower in the osteosarcoma as compared to that in the adenocarcinoma for ADM, MMC, CDDP, ACR and CQ (p < 0.01) and was higher for ADM (p < 0.05) in cases of leiomyosarcoma and for CDDP (p < 0.01) and ACR (p < 0.05) in cases of liposarcoma. The sensitivity rate was higher in osteosarcoma than in adenocarcinoma for ADM, MMC and CDDP. These findings suggest that patients with osteosarcoma will probably show a fairly good response to antitumor drugs and that when liposarcoma or leiomyosarcoma tumors show resistance to antitumor drugs then resection at the time of initial exploration and combined modalities, including radiation and hyperthemia should be considered.
UR - http://www.scopus.com/inward/record.url?scp=0028179983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028179983&partnerID=8YFLogxK
M3 - Article
C2 - 8166444
AN - SCOPUS:0028179983
SN - 0250-7005
VL - 14
SP - 169
EP - 171
JO - Anticancer research
JF - Anticancer research
IS - 1 A
ER -
